I-MAB/$IMAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Ticker
$IMAB
Sector
Primary listing
Employees
-
Headquarters
Website
I-MAB Metrics
BasicAdvanced
$550M
-
-$0.49
1.46
-
Price and volume
Market cap
$550M
Beta
1.46
52-week high
$5.90
52-week low
$0.60
Average daily volume
1.7M
Financial strength
Current ratio
22.817
Quick ratio
22.648
Long term debt to equity
1.336
Total debt to equity
1.769
Profitability
EBITDA (TTM)
-38.085
Management effectiveness
Return on assets (TTM)
-10.36%
Return on equity (TTM)
-18.46%
Valuation
Price to book
1.98
Price to tangible book (TTM)
1.98
Price to free cash flow (TTM)
8.936
Free cash flow yield (TTM)
11.19%
Free cash flow per share (TTM)
0.534
Growth
Earnings per share change (TTM)
-56.40%
3-year earnings per share growth (CAGR)
-50.34%
What the Analysts think about I-MAB
Analyst ratings (Buy, Hold, Sell) for I-MAB stock.
Bulls say / Bears say
I-Mab completed an underwritten offering of American Depositary Shares in August 2025, raising net proceeds of approximately $61.2 million to fund its clinical pipeline (GlobeNewswire).
Pro-forma cash balance of approximately $226.8 million as of June 30, 2025, is expected to fund operating expenses and capital requirements through the fourth quarter of 2028, providing a multi-year runway for clinical development (GlobeNewswire).
Positive Phase 1b combination data presented at ESMO GI 2025 showed givastomig achieved an 83% objective response rate at the doses selected for expansion, with rapid, durable responses and a favorable safety profile, underscoring its potential as a best-in-class therapy for first-line metastatic gastric cancer (GlobeNewswire).
In March 2025, I-Mab received a Nasdaq deficiency notice for failing to maintain the $1.00 minimum bid price requirement, risking potential delisting if compliance is not regained by September 15, 2025 (GlobeNewswire).
The August 2025 equity offering increased pro-forma shares outstanding to approximately 264.8 million from 188.1 million, diluting existing shareholders by over 40% (GlobeNewswire).
Key pipeline catalysts for ragistomig and uliledlimab are not expected until 2026, leaving investors with an extended period before material de-risking events (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
I-MAB Financial Performance
Revenues and expenses
I-MAB Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for I-MAB stock?
I-MAB (IMAB) has a market cap of $550M as of October 12, 2025.
What is the P/E ratio for I-MAB stock?
The price to earnings (P/E) ratio for I-MAB (IMAB) stock is 0 as of October 12, 2025.
Does I-MAB stock pay dividends?
No, I-MAB (IMAB) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next I-MAB dividend payment date?
I-MAB (IMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for I-MAB?
I-MAB (IMAB) has a beta rating of 1.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.